Versant Ventures related stories
All articles and analysis
Turnstone Biologics raises $80m in Series D financingTurnstone Biologics, a clinical-stage biotechnology company focused on developing cancer immunotherapies, has raised $80 million in Series D financing.
VC-backed Graphite Bio raises $238m for IPOGraphite Bio, a gene editing company focused on treating or curing serious diseases, has raised $238 million for its IPO after pricing its 14 million shares at $17 per share.
- VC-backed Monte Rosa Therapeutics debuts IPO
Monte Rosa Therapeutics Inc, a developer of small molecule precision medicines, has raised about $222.3 million for its IPO after pricing its 11.7 million shares at $19 per share.
- Lenz Therapeutics rallies $47m Series A
Lenz Therapeutics, a biopharmaceutical company, has raised $47 million in Series A financing.
- Bright Peak Therapeutics rakes in $107m Series B
Bright Peak Therapeutics, a developer of cytokine immunotherapies to treat cancer and autoimmune disease, has raised $107 million in Series B financing.
- Capsida Biotherapeutics rakes in $50m Series A
Capsida Biotherapeutics Inc., a biotechnology company, has secured $50 million in Series A funding.
- Ventus Therapeutics procures $100m in Series B round
Waltham, Massachusetts and Montreal-based biotechnology company Ventus Therapeutics has raised $100 million in a Series B financing.
Anzu Partners appoints one as principal and another as exec-in-residenceAnzu Partners has named Dr. Jaione Maiz as a principal and Andrew Sandford as an executive-in-residence.
- Questa Capital hires partner and finance VP
Questa Capital has named Dr. Aabed Meer as a partner and Katie Hemmerling as vice president of finance.
- VC-backed Turnstone Biologics buys Myst Therapeutics
Ottawa-based biotechnology company Turnstone Biologics has acquired Myst Therapeutics, a Los Angeles-based developer of novel T-cell therapies for solid tumors.